How Ultomiris Works Differently Than Soliris
Ultomiris (ravulizumab) and Soliris (eculizumab) share the same mechanism of action—both are terminal complement C5 inhibitors that prevent formation of the membrane attack complex—but Ultomiris is engineered with a significantly longer half-life (270-414 hours for eculizumab vs approximately 50 days for ravulizumab), allowing for extended dosing intervals of every 8 weeks instead of every 2 weeks. 1, 2
Identical Mechanism of Action
Both medications work by:
- Specifically binding to complement protein C5 with high affinity
- Inhibiting cleavage of C5 into C5a (proinflammatory anaphylatoxin) and C5b
- Preventing formation of the membrane attack complex (MAC or C5b-9)
- Blocking terminal complement-mediated intravascular hemolysis in PNH
- Inhibiting complement-mediated thrombotic microangiopathy in aHUS 1, 2
The FDA labels explicitly state that ravulizumab is a "humanized monoclonal antibody produced in Chinese hamster ovary (CHO) cells" while eculizumab is a "recombinant humanized monoclonal IgG2/4κ antibody produced by murine myeloma cell culture," but both target the same C5 protein with the same therapeutic goal 1, 2.
Key Pharmacologic Differences
Structural Engineering
Ravulizumab was specifically glycoengineered from eculizumab to extend its half-life through modifications that enhance its pharmacokinetic profile 3, 4. This engineering allows the antibody to remain in circulation substantially longer.
Dosing Intervals
- Soliris (eculizumab): Requires intravenous infusions every 2 weeks after initial loading 2
- Ultomiris (ravulizumab): Administered every 8 weeks after initial loading 1
This represents a 4-fold reduction in infusion frequency, which significantly decreases treatment burden 5.
Pharmacodynamic Profile
Both achieve complete C5 inhibition (free C5 <0.5 mcg/mL), but:
- Ultomiris maintains more sustained trough levels throughout the 8-week dosing interval 1
- Eculizumab may have more variable trough concentrations at the end of the 2-week interval 2
Recent real-world data suggests potential differences: one 2026 study found that at end-of-dose intervals, median alternative pathway (AH50) suppression was stronger with eculizumab (1%) than ravulizumab (5%), though both achieved therapeutic targets 6. However, this finding requires validation in larger studies.
Clinical Equivalence
The 2025 Italian multidisciplinary consensus explicitly states that "Eculizumab and Ravulizumab have the same efficacy in terms of endpoints, but Ravulizumab has a more favourable profile in relation to duration of effects, infusion frequency and costs." 5
Phase 3 trials demonstrated:
- Non-inferiority of ravulizumab to eculizumab for all approved indications
- Similar safety profiles between the two agents
- Numerically lower rates of breakthrough hemolysis with ravulizumab (p<0.0004 for non-inferiority) 3, 4
- Patient preference for ravulizumab due to less frequent dosing 3
Practical Implications
Advantages of Extended Dosing
- Reduced treatment burden: 6-7 infusions per year vs 26 infusions
- Improved quality of life through less frequent hospital visits
- Lower risk of breakthrough hemolysis between doses 3, 4
- Potentially better adherence due to convenience
Common Pitfalls
Both medications carry the same critical risk of meningococcal infection requiring:
- Quadrivalent A, C, W, Y meningococcal conjugate vaccine
- B meningococcal vaccine
- Long-term antimicrobial prophylaxis with penicillin (or macrolides if penicillin-allergic) 5
Clinical Caveat
While ravulizumab was designed for 8-week dosing, one 2026 real-world study found that 81% of myasthenia gravis patients experienced symptom recurrence before the next scheduled infusion, with higher AH50 levels correlating with earlier wearing off 6. This suggests some patients may require individualized dosing adjustments, though this finding needs validation across other indications.
Bottom Line for Practice
Ultomiris and Soliris are mechanistically identical C5 inhibitors—the only meaningful difference is pharmacokinetic engineering that allows Ultomiris to be dosed every 8 weeks instead of every 2 weeks, providing equivalent efficacy with substantially improved convenience. 5, 1, 2 The choice between them should prioritize patient convenience and quality of life, as clinical outcomes are equivalent 5, 3, 4.